Therefore, VEGF blockade, encompassing monoclonal antibody-based agents and VEGF receptor tyrosine kinase inhibitors, is currently the primary strategy for vascular normalization in GC (Yu et al. 2016). The gene discussed is VEGFA; the disease is gastric cancer.